Navigation Links
Watson Launches GELNIQUE(TM) (oxybutynin chloride) Gel 10%, First and Only Topical Gel for Overactive Bladder (OAB)

- Bold and innovative marketing campaign will target women and highlight product's efficacy, ease of use and excellent tolerability -

CORONA, Calif., May 21 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, a leader in generic and specialty branded pharmaceuticals, announced today the launch of GELNIQUE(TM) (oxybutynin chloride) gel 10%, first and only topical gel for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency.

While GELNIQUE is approved for use in men as well as women, Watson has opted to target the active, female OAB patient in its marketing efforts. The GELNIQUE marketing campaign will highlight the power of control GELNIQUE offers to OAB patients rather than focusing, as traditional products have, on the predictable embarrassment and stigma associated with OAB.

"As the first and only topical gel for OAB, we believe that GELNIQUE provides physicians and their patients with an effective, easy first-line drug treatment option," said Paul Bisaro, Chief Executive Officer of Watson. "Because GELNIQUE is a first, we are launching our product with a unique promotional campaign, one that speaks to health care professionals and patients with language and images that are empowering. We believe we can successfully position this new treatment option in a way that differentiates our product, and our message in a category that has been dominated by big pharma's tired and traditional promotion for years."

OAB is characterized by a sudden, uncomfortable need to urinate with or without urge incontinence (urine leakage), and usually includes more frequent urination and nocturia (waking up at least once during the night to urinate). It affects as many as 34 million adults in the U.S. - more than diabetes or asthma. The U.S. OAB market currently exceeds $1.8 billion annually and continues to grow each year. More than an "inconvenience," OAB is disabling and associated with a marked decrease in health-related quality of life as well as higher rates of depression. The disease affects both men and women however, women experience more severe symptoms earlier in life.

In addition to GELNIQUE, Watson recently launched RAPAFLO(TM) (silodosin), the Company's new alpha blocker for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH), which offers rapid relief and has an exceptional safety profile. The Company also has submitted a New Drug Application for its 6-month formulation of TRELSTAR(R) (triptorelin pamoate), a luteinizing hormone releasing hormone (LHRH) agonist for the palliative treatment of advanced prostate cancer. Watson anticipates that FDA will take action on this application in the third quarter 2009.


GELNIQUE is a quick-drying, clear and colorless, fragrance-free hydroalcoholic gel containing oxybutynin chloride, an antispasmodic antimuscarinic agent. Applied once daily to the thigh, abdomen, upper arm or shoulder, one-gram (approx. 1 mL) of GELNIQUE gel 10% delivers a consistent dose of oxybutynin through the skin over a 24-hour period, providing strong efficacy with excellent tolerability.

Because the active ingredient in GELNIQUE is delivered transdermally, it is not metabolized in the same way as orally administered oxybutynin. It bypasses fist-pass metabolism, which reduces the formation of the N-desethyloxybutynin metabolite (N-DEO), which may be linked to unwanted side effects such as dry mouth and constipation. In clinical trials, GELNIQUE users reported low levels of dry mouth (6.9%) and constipation (1.3%).

In a Phase 3, 12-week trial, one-gram, once-daily GELNIQUE was superior to placebo at relieving OAB symptoms, including a reduction in incontinence episodes and urinary frequency, and an increase in urine void volume. The treatment was well tolerated in the study with a low incidence of adverse events and no treatment-related serious adverse events. The most frequently reported treatment-related adverse events (>2% and greater than placebo) were dry mouth and application-site reactions (5.4%).

Additional pharmacology studies showed that showering one hour or later, or applying sunscreen lotion 30 minutes before or after GELNIQUE application, did not significantly alter the absorption of the drug.

For full prescribing information, please visit

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc., (NYSE: WPI) is a global leader in the development and distribution of pharmaceuticals with a broad portfolio of generic products and a specialized portfolio of branded pharmaceuticals focused on Urology, Gynecology and Nephrology (Medical).

In the U.S., the Watson portfolio includes RAPAFLO, GELNIQUE, TRELSTAR(R) LA and TRELSTAR(R) Depot, Ferrlecit(R), INFeD(R) and Oxytrol(R). In addition, Watson markets the following brands under co-promotion agreements: AndroGel(R), with Solvay Pharmaceuticals, Inc., and Femring(R), with Warner Chilcott Limited. The Watson pipeline portfolio includes a number of products, including a six-month formulation of TRELSTAR(R), for the treatment of advanced prostate cancer which is currently under review by the FDA; URACYST(R), under development for cystitis; and a novel new oral contraceptive.

For press releases and other company information, visit the Watson website at

Forward-Looking Statement

Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, the impact of competitive products and pricing; market acceptance of and continued demand for Watson's products, including GELNIQUE; the difficulty of predicting the timing or outcome of FDA approvals and actions, if any; and other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Annual Report on Form 10-K for the year ended December 31, 2008.

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Watson-Marlow Releases Informative Video Featuring Showcased High Purity Pumps, Tubing and Fillers at Interphex 2009
2. Watson Pharmaceuticals Reports First Quarter 2009 Results; Raises 2009 Outlook
3. Watson Files FDA Applications for Generic Mucinex(R)
4. Watson to Host and Webcast Investment Community Meeting at American Urological Association Annual Meeting
5. Companies Continue To Add Wellness Programs, Watson Wyatt/National Business Group On Health Survey Finds
6. Mark G. Watson Named Executive Director of Radiological Society of North America
7. Watson Pharmaceuticals and Elan Settle Lawsuit Over Naproxen Sodium
8. Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook
9. Watson Acknowledges Federal Trade Commission Action Regarding AndroGel Patent Settlement
10. Warner Chilcott and Watson Pharmaceuticals Announce Agreements on Loestrin(R) 24 and Femcon(R) Fe Patent Litigation
11. Watson Pharmaceuticals Receives FDA Approval for Mint Coated Nicotine Gum
Post Your Comments:
(Date:10/13/2015)... ... October 13, 2015 , ... ... kind product that targets the unique health needs of new moms. Postnatal ... Pregnancy Association ( ), utilizes Nordic Naturals’ exclusive, new, ultra-concentrated omega-3 ...
(Date:10/13/2015)... ... 2015 , ... California Southern University has named Dr. Judith ... Doctor of Nursing Practice from the renowned Johns Hopkins University—comes to CalSouthern with ... McLeod’s long and successful nursing practice included a variety of patient care, education ...
(Date:10/13/2015)... , ... October 13, 2015 , ... ... Bill Saye as the newest professional to introduce the latest development, ThermiVa® temperature ... recognized as a leading professional in Obstetrics and Gynecology and a pioneer in ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... home furnishings and décor, today announced it closed on a $20.5 million funding ... will be used to support the Company’s continued rapid growth and expansion, broaden ...
(Date:10/13/2015)... ... 2015 , ... The Bill Howe Family of Companies is an award winning ... flood remediation services. Family-owned and operated for 35 years, they have maintained value, ethics ... plumber two years in a row from the Union Tribune Reader’s Poll, a Healthiest ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)... N.C. , Oct. 13, 2015  Yesterday Congresswoman ... Influenza Vaccines Holly Springs manufacturing site located in ... 2014, the facility has produced Flucelvax ® (Influenza ... the potential for faster start-up and is not reliant ... CSL Limited acquired the influenza vaccines business of Novartis ...
(Date:10/12/2015)... 12, 2015 Given the intricacy of ... challenging to deliver an ophthalmic drug effectively to a specific ... successful ocular drug delivery. These include dilution of a drug ... of conjunctiva and drug permeation issues with respect to the ... topical eye drops, is lost due to the aforementioned barriers. ...
(Date:10/12/2015)... CRANBURY, N.J. , Oct. 12, 2015 /PRNewswire/ ... that a securities fraud class action complaint was ... of New Jersey.  The complaint alleges that officers and ... Securities Exchange Act of 1934 between September 15, 2015 ... misleading statements about Amicus Therapeutics, business prospects.  Amicus is ...
Breaking Medicine Technology: